Skip to Content
Merck
All Photos(1)

Documents

SML0029

Sigma-Aldrich

Glycopyrrolate

≥98% (HPLC)

Synonym(s):

α-cyclopentylmandelic acid ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide, 1-methyl-3-pyrrolidyl α-cyclopentylmandelate methobromide, 1-methyl-3-pyrrolidyl α-phenyl-α-cyclopentylglycolate methobromide, 3-(2-phenyl-2-cyclopentylglycoloyloxy)-1,1-dimethylpyrrolidinium bromide, 3-hydroxy-1,1-dimethylpyrrolidinium bromide α-cyclopentylmandelate, AHR-504, Copyrrolate, Gastrodyn, NSC 250836, NSC 251251, NSC 251252, NVA-237, glycopyrronium bromide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H28NO3 · Br
CAS Number:
Molecular Weight:
398.33
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to tan

solubility

H2O: ≥24 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

[Br-].C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)c3ccccc3

InChI

1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1

InChI key

VPNYRYCIDCJBOM-UHFFFAOYSA-M

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

Glycopyrrolate is a quaternary ammonium compound and it shows structural similarity with atropine.

Biochem/physiol Actions

Glycopyrrolate is an anti-cholinergic drug. It is a potent controller of drooling, observed in children affected with cerebral palsy. Compared to other muscarinic antagonists, glycopyrrolate has lower CNS (central nervous system) penetration.
Glycopyrrolate is long-acting muscarinic antagonist (LAMA). It is kinetically selective muscarinic M3 receptor antagonist.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Kiril A Ahtarovski et al.
American journal of physiology. Heart and circulatory physiology, 303(12), H1469-H1473 (2012-10-23)
The aim of this study is to describe phasic volume changes of the left atrium (LA) in healthy young and elderly subjects at rest and during pharmacological stress (PS). LA maximum size is related to cardiovascular mortality. LA has passive
David A Sykes et al.
The Journal of pharmacology and experimental therapeutics, 343(2), 520-528 (2012-08-03)
Studies under nonphysiological conditions suggest that long receptor residency time is responsible for the 24-h duration of action of the long-acting muscarinic antagonist (LAMA) tiotropium. Our aim was to determine how clinically relevant dissociation rates under more physiological conditions influence
Charlotte V Rosenstock et al.
Anesthesiology, 116(6), 1210-1216 (2012-04-11)
Awake flexible fiberoptic intubation (FFI) is the gold standard for management of anticipated difficult tracheal intubation. The purpose of this study was to compare awake FFI to awake McGrath® video laryngoscope, (MVL), (Aircraft Medical, Edinburgh, Scotland, United Kingdom) intubation in
Edward Kerwin et al.
The European respiratory journal, 40(5), 1106-1114 (2012-10-13)
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52
Roland Buhl et al.
International journal of chronic obstructive pulmonary disease, 7, 729-741 (2012-11-03)
Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service